NCT02593500View on ClinicalTrials.gov

Bioequivalence Study of Two Inhalation Formulations Containing Budesonide 200 µg

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Allergy
Interventions
DRUG

Budesonida Pulmictan® 200 µg

DRUG

Budesonide 200 µg

Trial Locations (1)

9301

Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein

All Listed Sponsors
lead

Reig Jofre Group

INDUSTRY

NCT02593500 - Bioequivalence Study of Two Inhalation Formulations Containing Budesonide 200 µg | Biotech Hunter | Biotech Hunter